CareCloud, Inc.
NASDAQ:CCLDMedical - Healthcare Information Services
+$0.04 today
- Market cap
- $101.27M
- Beta
- 1.51
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.23
Volume 0.53M
Average 0.58M
CCLD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CareCloud, Inc.NASDAQ: CCLD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of $5.53M rose 1.4% year over year, behind the +17.2% change in trailing-twelve-month EBITDA. Sequentially, it fell 38.4% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- EBITDA amounted to 23.5% of revenue in FY2025, up 0.9 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $24.34M (-13.9%) for the fiscal year ending Dec 2026, a slowdown from the +12.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.53M-38.4% QoQ
- Last fiscal yearDec 2025
- $28.26M+12.8% YoY
- LTMMar 2026
- $28.3M+17.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.4% | +4.3% | +2.9 pp |
| 1 year | +12.8% | -13.9% | -26.7 pp |
| 3-year CAGR | +10.4% | +6.3% | -4.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 28.26M USD
- Year-over-year change
- +12.8%
- 4-year CAGR
- +9.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.26M | +12.8% |
| FY2024 | 2024-12-31 | 25.05M | +180.0% |
| FY2023 | 2023-12-31 | (31.29M) | -248.8% |
| FY2022 | 2022-12-31 | 21.03M | +6.7% |
| FY2021 | 2021-12-31 | 19.7M | — |
EBITDA vs competitors
How CCLD compares with its peers on the latest reported figures
- CCLD's LTM Mar 2026 EBITDA of $28.3M is the 2nd highest of the 10 companies compared; the peer median is -$30.19M.
- Its year-over-year change of +17.2% is the 6th highest of 9, against a peer median of +23.3%.
- EBITDA amounts to 22.8% of revenue for CCLD, versus a peer median of 131.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
| LTM Mar 2026 | $28.3M | +17.2% | +10.4% | 22.8% | |
| LTM Mar 2026 | $2.94M | +2328.8% | -42.7% | 5.2% | |
| LTM Mar 2026 | -$2.44M | +81.8% | — | 4.4% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$3.79M | — | — | — |
| LTM Mar 2026 | -$30.19M | -68.1% | — | — | |
| LTM Mar 2026 | -$44.12M | +27.6% | — | 859.3% | |
| LTM Mar 2026 | -$45.12M | -8.6% | — | 131.2% | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
| Peer median (excluding CCLD) | -$30.19M | +23.3% | -42.7% | 131.2% | |
Competitors are the stored peer set for CCLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.6M | 138.83M | 117.06M | 110.84M | 120.5M |
| Cost of Revenue | 86.92M | 84.43M | 70.82M | 60.84M | 64.46M |
| Gross Profit | 52.68M | 54.39M | 46.24M | 50M | 56.04M |
| Gross Margin | 37.7% | 39.2% | 39.5% | 45.1% | 46.5% |
| Research & Development | 4.41M | 4.4M | 4.74M | 3.78M | 6.38M |
| Selling, General & Admin | 33.06M | 33.61M | 31.11M | 22.36M | 23.2M |
| Operating Expenses | 49.15M | 47.78M | 93.36M | 40.87M | 44.55M |
| Depreciation & Amortization | 16.25M | 15.01M | 16.55M | 16.14M | 16.98M |
| EBITDA | 19.7M | 21.03M | (31.29M) | 25.05M | 28.26M |
| EBITDA Margin | 14.1% | 15.1% | -26.7% | 22.6% | 23.5% |
| Operating Income | 3.53M | 6.61M | (47.12M) | 9.12M | 11.5M |
| Operating Margin | 2.5% | 4.8% | -40.2% | 8.2% | 9.5% |
| Interest Income | 15K | 41K | 154K | 88K | 206K |
| Interest Expense | 455K | 405K | 1.19M | 900K | 287K |
| Other Income / Expenses | (536K) | (1M) | (1.92M) | (1.11M) | (500K) |
| Income Before Tax | 2.99M | 5.61M | (49.04M) | 8.01M | 11M |
| Pre-Tax Margin | 2.1% | 4.0% | -41.9% | 7.2% | 9.1% |
| Income Tax Expense | 157K | 177K | (364K) | 160K | 199K |
| Net Income | 2.84M | 5.43M | (48.67M) | 7.85M | 10.8M |
| Net Margin | 2.0% | 3.9% | -41.6% | 7.1% | 9.0% |
| EPS (Basic) | (0.77) | (0.67) | (4.11) | (0.28) | 0.10 |
| EPS (Diluted) | (0.77) | (0.67) | (4.11) | (0.28) | 0.10 |
| Weighted Avg Shares | 14.54M | 15.11M | 15.67M | 16.15M | 377.92M |
| Weighted Avg Shares (Diluted) | 14.54M | 15.11M | 15.67M | 16.15M | 379.54M |
CareCloud, Inc.
NASDAQ:CCLD
Intrinsic Alpha fair value
Locked
Current Price
$2.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.